CIP
ANIK icon

Convergence Investment Partners’s Anika Therapeutics ANIK Stock Holding History

Convergence Investment Partners’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,645
Closed -$145K – 227
2019
Q3 		$145K Buy
+2,645
New +$136K 0.04% 257
2014
Q3 		– Sell
-16,046
Closed -$743K – 363
2014
Q2 		$743K Buy
+16,046
New +$714K 0.1% 277

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Convergence Investment Partners's ANIK Position: Q4 2019 in Review

Convergence Investment Partners sold out of Anika Therapeutics (ANIK) in Q4 2019, closing a stake of 2,645 shares — an estimated $145K sold.

Convergence Investment Partners first reported a position in ANIK in Q2 2014 and held it in 2 quarters. The position peaked at $743K in Q2 2014. 191 funds tracked by Wall St. Rank hold ANIK as of Q4 2019.

  • Convergence Investment Partners reported no remaining Anika Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Convergence Investment Partners sold 2,645 Anika Therapeutics shares in Q4 2019, an estimated $145K.
  • Convergence Investment Partners first reported a position in Anika Therapeutics in Q2 2014 and held it in 2 quarters.
  • Convergence Investment Partners's Anika Therapeutics position peaked at $743K in Q2 2014.
  • 191 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2019.

Based on Convergence Investment Partners's 13F filing for Q4 2019, filed 22 Jan 2020.